NCT02174575

Brief Summary

  • It has been shown that patients who undergo liver resection surgery are at high risk for postoperative acute kidney injury (AKI).
  • Sevoflurane may increase the risk for postoperative AKI because of production of compound-A.
  • Therefore, we have planned to investigate the effects of different anesthetic agents on postoperative renal function.
  • Patients undergoing liver resection surgery are randomized into 2 groups.
  • One of the groups receives sevoflurane and the other group receives desflurane.
  • Blood and urine specimen are sampled both pre- and postoperatively, and several biomarkers are compared between the groups.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2014

Longer than P75 for phase_4 hepatocellular-carcinoma

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 20, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 25, 2014

Completed
6 days until next milestone

Study Start

First participant enrolled

July 1, 2014

Completed
8.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2023

Completed
Last Updated

May 3, 2023

Status Verified

May 1, 2023

Enrollment Period

8.8 years

First QC Date

June 20, 2014

Last Update Submit

May 1, 2023

Conditions

Keywords

Hepatectomy

Outcome Measures

Primary Outcomes (1)

  • Postoperative acute kidney injury

    Postoperative acute kidney injury is defined based on RIFLE creatinine criteria.

    within 72 hours postoperatively

Secondary Outcomes (7)

  • Urine IL-6 concentration

    On the day of surgery and postoperative day 1

  • Plasma NGAL concentration

    On the day of surgery and postoperative day 1

  • Urine NGAL concentration

    On the day of surgery and postoperative day 1

  • Serum cystatin C concentration

    On the day of surgery and postoperative day 1

  • Urine L-FABP concentration

    On the day of surgery and postoperative day 1

  • +2 more secondary outcomes

Study Arms (2)

Sevoflurane

ACTIVE COMPARATOR

Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.

Drug: Sevoflurane

Desflurane

ACTIVE COMPARATOR

Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.

Drug: Desflurane

Interventions

Sevoflurane is administered during anesthesia in Sevoflurane group.

Sevoflurane

Desflurane is administered during anesthesia in Desflurane group.

Desflurane

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Forty adult patients (20 patients in each group) who are planned to undergo liver resection surgery are included.

You may not qualify if:

  • Patients who undergo less invasive resection surgery under thoracoscopy or laparoscopy are excluded. Patients with chronic kidney disease, or allergic to any anesthetic agents used in the study are also excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tokyo Medical and Dental University

Tokyo, 113-8519, Japan

Location

MeSH Terms

Conditions

Carcinoma, HepatocellularCholangiocarcinomaGallbladder Neoplasms

Interventions

SevofluraneDesflurane

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver DiseasesBiliary Tract NeoplasmsBiliary Tract DiseasesGallbladder Diseases

Intervention Hierarchy (Ancestors)

Methyl EthersEthersOrganic ChemicalsHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbonsEthyl Ethers

Study Officials

  • Koshi Makita, M.D.

    Tokyo Medical and Dental University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 20, 2014

First Posted

June 25, 2014

Study Start

July 1, 2014

Primary Completion

May 1, 2023

Study Completion

May 1, 2023

Last Updated

May 3, 2023

Record last verified: 2023-05

Locations